CGG S.A.: announces a consent solicitation in respect of its Senior Notes and Term Loan B
Feb 06, 2017 06:31 am UTC| Business
CGG S.A. announces a consent solicitation in respect of its Senior Notes and Term Loan B Paris, France - February 6, 2017 CGG S.A. ("CGG") today announces that it is soliciting consents (the "Solicitation") to...
Global Melanoma Drugs Market will reach USD 4.71 Billion by 2022: Zion Market Research
Feb 06, 2017 06:06 am UTC| Business
Sarasota, FL, Feb. 06, 2017 -- Zion Market Research has published a new report titled “Melanoma Drugs Market by Therapy (Chemotherapy, Immunotherapy and Targeted Therapy) and Region: Global Industry Perspective,...
Feb 06, 2017 06:01 am UTC| Business
In the Phase II TITAN study, treatment with caplacizumab significantly reduced the time to platelet count normalisation and the number of recurrences of aTTP while on drug treatment Post-hoc analysis of the TITAN study...
INNATE PHARMA announces top-line results from EffiKIR trial evaluating the efficacy of lirilumab
Feb 06, 2017 06:01 am UTC| Business
Innate Pharma announces top-line results from EffiKIR trial evaluating the efficacy of lirilumab as a single agent in elderly patients with acute myeloid leukemia The study did not meet the primary efficacy endpoint...
Feb 06, 2017 06:00 am UTC| Business
Oslo, Norway, 6 February 2017 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, will announce its fourth quarter and full year 2016 results on...
Feb 06, 2017 06:00 am UTC| Business
LOS ANGELES, Feb. 05, 2017 -- Oracle (NYSE:ORCL) and Apollo Enterprise Solutions, Ltd. (“AES” or “The Company”) (AES:BH) (OAL:GR), a Gold level member of the Oracle PartnerNetwork, have achieved Oracle Validated...
Genmab Announces Updated 2016 Financial Guidance
Feb 06, 2017 05:40 am UTC| Business
Company Announcement Copenhagen, Denmark; February 6, 2017 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that it has updated its 2016 Financial Guidance. Based on preliminary reporting, Genmab is improving its...